Bristol, 9th February 2022 – Bristol based, eXmoor Pharma is pleased to announce the appointment of Dr. Lucy Foley as Chief Technology Officer.

Lucy brings with her more than 10 years of industry experience focused on technology, process development and delivering large, complex projects. Her role will see her oversee the vector, analytics, cell therapy, and project verticals.

Lucy commented: “I’m thrilled to have joined eXmoor and to have the opportunity to work alongside Angela and the board. I am excited to be part of the growth journey eXmoor is on and its significant contribution to growing the UK as a world leader in cell and gene therapies.

Lucy joins eXmoor after eight years at the Centre for Process Innovation (CPI) with her most recent position as Director of Biologics and COVID response.

She recently led the establishment of the UK’s RNA Centre of excellence in response to the COVID-19 pandemic as a member of the UK Vaccines Taskforce. This established both PD and GMP facilities in the UK to provide resilience against future variants and pandemics by onshoring manufacturing and expertise.

In 2013, as the Lead Biopharmaceutical Engineer at CPI, Lucy collaborated with eXmoor on the concept design of the organisation’s Darlington-based National Biologics Manufacturing Centre.

Previously, she was an academic at Newcastle University in both the Business School and Chemical Engineering Departments where she worked with Professors Lyddiatt and Whitaker to understand the route to widespread adoption and process industrialisation of advanced therapies.

Lucy is already a familiar face to the eXmoor team as she serves as a founding leadership team member on the amc (ATMP Manufacturing Community) board alongside eXmoor CEO, Dr. Angela Osborne.

Angela Osborne commented: “I welcome Lucy to our growing team here at eXmoor. Her unprecedented industry experience will be integral to the next phase of our growth.”

Lucy holds a master’s degree in biochemical engineering with bioprocess management from University College London, and an engineering doctorate in biochemical engineering and bioprocess leadership from University College London.